GamaSTAN™ S/D

 

Manufacturer: Talecris Biotherapeutics
Generic Name: Intramuscular Immune Globulin (Human) / Solvent Detergent

Indications:
Hepatitis A: The prophylactic value of GamaSTAN S/D is greatest when given before or soon after exposure to hepatitis A. GamaSTAN S/D is not indicated in persons with clinical manifestations of Hepatitis A or in those exposed more than 2 weeks previously.
Measles (Rubeola): GamaSTAN S/D should be given to prevent or modify measles in a susceptible person exposed fewer that 6 days previously. A susceptible person is one who has not been vaccinated and has not had measles previously. GamaSTAN S/D may be especially indicated for susceptible household contacts of measles patients, particularlry contacts under 1 year of age, for whom the risk of complications is highest. GamaSTAN S/D and measles vaccine should not be given at the same time. If a child is older than 12 months and has received GamaSTAN S/D, he should be given measles vaccine about 3 months later when the measles antibody titer will have disappeared.

If a susceptable child exposed to measles is imunocompromised, GamaSTAN S/D should be given immediately Children who are immunocompromised should not receive measles vaccine or any other live viral vaccine.

Varicalla: Pasive immunization against varicella in immunosupressed patients is best accomplished by use of Varicella Zoster Immune Globulin (Human) [VZIG]. If VZIG is unavailable, GamaSTAN S/D, promptly given, may also modify varicella.

Rubella: The routine use of GamSTAN S/D for prophylaxis of rebuella in early pregnancy is of dubious value and cannot be justified. Some studies suggest that the use of GamaSTAN S/D in exposed, susceptible women can lessen the likelihood of infection and fetal damage; therefore, GamaSTAN S/D may benefit those women who will not consider a therapeutic abortion.

Immunoglobulin Deficiency: In patients with immunoglobulin deficiencies, GamaSTAN S/D may prevent serious infection. However, GamaSTAN S/D may not prevent chronic infections of the external secretory tissues such as the respiratory and gasrointestinal tract. Prophylactic therapy, especially against infections due to encapsulated bacteria, is effective in Bruton-type sex-linked, congenital agammaglobulinemia, agammaglobulinemia associated with thymoma, and acquired agammaglobulinemia.

GamaSTAN™ S/D Product Insert

Available Sizes

NDC Numbers

GamaSTAN™ S/D 2ml vial

13533-0635-04

GamaSTAN™ S/D 2ml vial 10 pack

13533-0635-02

GamaSTAN™ S/D 10ml vial

13533-0635-12

GamaSTAN™ S/D 10ml vial 10 pack

13533-0635-10

http://www.talecris.com